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morbidity and mortality is highly desirable. Elevated albu-
minuria levels have proven to predict worse cardiovascular
outcomes. The aim of our study was to estimate the cost-
effectiveness and of a population-based ‘screen-and-treat’ proce-
dures directed at albuminuria. METHODS: A formal cost-
effectiveness analysis was conducted using a Markov-model
for disease progression. The model consist of 8 health states
deﬁned by urinary albumine excretion (UAE) classiﬁcation
(UAE < 15 mg/day (low-normo), UAE 15–30 mg/day (high-
normo), UAE 30–300 mg/day (micro), 300 mg/day (macro)),
cardiovascular morbidity, cardiovascular mortality, non-
cardiovascular mortality and renal disease (e.g. dialysis). Input-
variables for transitions between albuminuria-based Markov
stages and effects of blood pressure lowering agents were
derived from the observational PREVEND cohort study and
PREVEND-IT clinical trial. All costs were presented in 2008
values and the cost-effectiveness analysis was performed follow-
ing the Dutch guidelines for conducting pharmacoeconomic
research. RESULTS: Early results for screening the Dutch popu-
lation on albuminuria (15 mg/day) and subsequent ACE-
inhibitor treatment in those found positive, suggests a crude
cost-effectiveness of €29,300 per life year gained (LYG). Treating
only those subjects with microalbuminuria (30 mg/day)
resulted to be more favorable with a cost-effectiveness of €9700
per LYG. Furthermore, restricting screening to only those
subjects aged >50 or >60 years resulted in a cost-effectiveness of
respectively €15,000 and €10,200 per LYG. These age-dependent
ﬁgures were even more favorable in those subjects with
microalbuminuria. Our preliminary results suggest a favorable
cost-effectiveness outcome below the (informal) Dutch pharma-
coeconomic threshold of €20,000 per LYG. CONCLUSIONS:
Next to the cost-effectiveness outcomes from the PREVEND-IT
economic evaluation, our results on observational data suggest
favorable cost-effectiveness outcomes for a population-based
‘screen-and-treat’ procedure on albuminuria. Deﬁnite results
including probabilistic sensitivity analyses will be presented
during the conference.
PCV43
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OBJECTIVES: To compare the short-term cost-effectiveness of
simultaneously achieving multiple lipid targets when fenoﬁbric
acid (FA) is co-administered with simvastatin, rosuvastatin, and
atorvastatin. METHODS: A dyslipidemia outcomes model was
used to estimate multiple lipid goal attainment (any 3 of 4
targets: total-C, LDL-C, HDL-C, TG) and associated costs over
one year in a patient cohort with multiple lipid abnormalities.
Lipid goal threshold values were based on U.S. clinical practice
guidelines. Baseline lipid values and lipid efﬁcacy data were
obtained from three 12-week FA/statin studies, where FA 135 mg
co-administered with atorvastatin, rosuvastatin, and simvastatin
at low (20 mg, 10 mg, 20 mg, respectively) and moderate doses
(40 mg, 20 mg, 40 mg, respectively) was compared to FA and
equivalent doses of each statin monotherapy. Net drug costs were
estimated. Drug costs were based on wholesale acquisition costs
and were assumed additive. Patient copays were based on
national averages. RESULTS: The predicted rate per 1,000
patients achieving 3 lipid targets with the co-administration of
FA and low-dose simvastatin, rosuvastatin, and atorvastatin was
678, 814, and 723, respectively. Per member per month drug
costs for each low-dose combination were estimated at $24.09,
$39.63, and $41.40, respectively. The estimated per patient costs
per three lipid goals achieved were $1279, $1753, and $2062 for
each respective low-dose combination. The incremental cost
effectiveness ratio (ICER) for one additional patient achieving 3
lipid targets when FA is combined with low-dose rosuvastatin
and atorvastatin relative to simvastatin is $4,113 and $13,849,
respectively. For the moderate-dose combinations, qualitative
results are similar though ICERs versus simvastatin for rosuvas-
tatin and atorvastatin were 1.4–11.2 times higher, respectively.
CONCLUSIONS: Adding FA 135 mg to simvastatin 20 mg and
40 mg yields the lowest annualized cost per patient achieving 3
lipid targets compared to equivalent dose combinations of FA
with rosuvastatin and atorvastatin.
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OBJECTIVES: An ICM is a programmable monitoring system
that stores a patient’s subcutaneous ECG and other diagnostic
information. Its features are aimed at detecting arrhythmias and
their long term trending. Since long-term continuous AF moni-
toring is not yet used in patients with PAAF in Spain, its impli-
cations in the management of these patients (including possible
OAC discontinuation) are still unknown. This study aimed to
model the cost-effectiveness of OAC management using ICMs in
patients treated with radiofrequency catheter ablation for atrial
ﬁbrillation (PAAF) in Spain. METHODS: A Markov model was
built to simulate the outcomes and costs of Standard of Care
(SOC, traditional intermittent 24H monitors) and continuous
AF monitoring with an ICM (Reveal XT). Efﬁcacy data was
obtained from clinical studies showing that Reveal was able to
detect asymptomatic episodes in AF patients, thus facilitating an
optimized disease management that may reduce long-term com-
plications incidence. The risks of stroke, adverse events manage-
ment and utility ﬁgures where taken from international
literature; local Spanish costs where used to model the economic
consequences of PAAF for three years. Costs and effects were
discounted at 3%. RESULTS: Model results show that the con-
tinuous long-term AF monitoring with ICMs may be associated
to a gain of 0.16 at an extra cost of €6100, showing an iCER of
€37,994 per QALY gained. Sensitivity analysis showed an impor-
tant uncertainty regarding the effectiveness of ICMs, with a 95%
CI of QALY gains of 0.11–0.21. CONCLUSIONS: The prelimi-
nary results of this study show that ICMs may improve PAAF
outcomes but extra health care costs are to be considered. Longer
follow-up analyses and inclusion of eventual quality of life gains
associated to the reduction of uncertainty of patients regarding
their disease, may improve the economic value of this novel
strategy using AF monitoring systems.
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OBJECTIVES: In the Eplerenone Post-Acute Myocardial Infarc-
tion Heart Failure Efﬁcacy and Survival Study (EPHESUS),
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eplerenone decreased cardiovascular mortality and deaths from
any cause by 15% (p = 0.008) in patients with acute myocardial
infarction complicated by left ventricular dysfunction and heart
failure. An economic evaluation was performed to asses the
cost-effectiveness of epleronone vs. placebo through patient life-
time in the Spanish setting. METHODS: The cost-effectiveness of
eplerenone in cost per Life-Year (LYG) and Quality-Adjusted-
Life-Years (QALY) gained compared to placebo was estimated.
Efﬁcacy data from EPHESUS study during the 16 month
follow-up period were used. Survival data beyond trial period
were estimated from the Framingham Heart Study Registry. The
study was carried out from societal perspective; therefore, only
direct medical costs where included. Drug acquisition costs were
priced at AWP (average wholesale price), €2007. Costs were
obtained from Spanish databases. Costs and effects were dis-
counted 3% annually. Sensitivity analyses were carried out based
on alternative life-years gained estimates from the Saskatchewan
Health database and Worcester Heart Attack Registry Data,
(0.0636 and 0.1337 respectively). RESULTS: The number of
LYG with eplerenone was 0.1014 based on Framingham. Cost
was €1016.90 higher over the trial period in the eplerenone arm
because of drug cost (€1,164.07). The Framingham incremental
cost-effectiveness ratio (ICER) of eplerenone compared to
placebo was 10,030€ per LYG and 15,047€ per QALY gained.
Sensitivity analyses showed eplerenone was efﬁcient under
alternative life expectancy estimates: €15,99€ per LYG with
Saskatchewan and €7,60€ per LYG with Worcester. CONCLU-
SIONS: Selective aldosterone blockade with eplerenone is a cost-
effective strategy in post-AMI patients with heart failure in Spain.
In addition to standard therapy, eplerenone prevents events,
saves hospitalization resources and improves survival among
these patients.
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OBJECTIVES: Clopidogrel has shown to be cost-effective to
prevent ischemic events in non-ST segment elevation acute coro-
nary syndromes (NSTEACS). This study is intended to assess
the cost-effectiveness of clopidogrel in long-term treatment of
ST-segment elevation myocardial infarction (STEMI) in Spain.
METHODS: A combined decision tree and Markov model was
constructed. Efﬁcacy data was obtained from CLARITY and
COMMIT trials for the ﬁrst month, and the “CAPRIE-like”
cohort of CHARISMA trial (months 2–12). The risks of death,
myocardial infarction, and stroke in an untreated population and
long-term survival after all events were derived from the Swedish
Hospital Discharge and Cause of Death register. A payer perspec-
tive was chosen for the analysis, using local costs. Effectiveness
was measured as the number of life-years gained (LYG) with
clopidogrel treatment. Costs and effects were discounted at 3%.
RESULTS: The difference in stroke rates was more pronounced
in CLARITY (0.9% vs. 1.7% and 0.55% vs. 0.62% in the
CLARITY and COMMIT respectively) and thus facilitates
important cost savings. In two patient cohorts with the same
characteristics and event rates as in the CLARITY and COMMIT
population, treatment with clopidogrel for up to 1 year opposed
to treatment with ASA resulted in ICERs (€/LYG)of: in
CLARITY cohort €397 and in COMMIT cohort €2927. CON-
CLUSIONS: Treatment of STEMI patients with clopidogrel
appeared to be cost-effective in long-term with predicted ICERs
below generally accepted threshold value of €30,000/LYG.
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OBJECTIVES: Abdominal Aortic Aneurysm (AAA) is deﬁned as
a localized dilatation of aortic vessel. It’s predominantly asymp-
tomatic, but represents a chronic degenerative condition associ-
ated with life-threatening risk of rupture. The early diagnosis of
AAA, i.e. before its ruptures, is therefore important and ultra-
sound examination is a simple and effective method for this.
To asses beneﬁt of screening in Italy we developed a cost-
effectiveness Markov model comparing screening vs non screen-
ing scenario. METHODS: We considered a patient cohort
composed of 65 years old men screened for AAA in the Italian
NHS perspective and compared it to a non-screened population.
We collected data both from literature and from a real screening
program that is on-going in San Martino Hospital in Genova.
The following health states were distinguished: no AAA,
unknown small-AAA (3–3.9 cm), followed-up small-AAA (1
year), unknown medium-AAA (4–4.9 cm), followed-up medium-
AAA (6 months), unknown large-AAA (>5 cm), elective repair,
emergency repair, electively repaired AAA, emergency repaired
AAA, rejected large AAA and death. Transition between health
states were simulated using 6-month cycles. Incremental cost per
life year saved was calculated for a 35-year time horizon and
applying a 3% discount rate to both cost and beneﬁts. RESULTS:
Considering an attendance rate of 70%, the individual cost per
invited subject was €104.42. 0.024 additional life years was
gained per patient in the screened cohort, corresponding to an
ICER of €4363/LYS. Univariate and multi-variate sensitivity
analyses were performed for all parameters. The results were not
sensitive to changes in parameters and suggest that screening for
AAA is cost-effective with a probability approaching 100%
based on a willingness-to-pay threshold of €30,000. CONCLU-
SIONS: Similarly to economic evaluations developed in other
countries like UK, Canada, etc, the setting up of a screening
program for AAA can be considered to be cost-effective in the
Italian NHS perspective.
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OBJECTIVES: Recent progress has enabled physicians to meet
the challenge of syncope diagnosis and provide faster and better
guided treatment to the patient. Syncope investigation tradition-
ally included loosely-deﬁned combinations of ECGs, Holter
Monitors, Tilt Tests, EP Studies and Imaging Diagnostics. While
tests were being performed, patients remained at risk of death,
falls and fractures. We wanted to examine the potential cost-
effectiveness of adding an Implantable Loop Recorder to the
traditional clinical pathway. Clinical evidence increasingly dem-
onstrates that ILR-enhanced diagnostics may enable physicians
to achieve more clear diagnoses, at a fraction of the time.
METHODS: We developed a decision-analytic model in
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